mTOR inhibitors are currently approved to treat various cancers, such as renal cell carcinomas, neuroendocrine tumours, and breast cancer [35] and have shown promise as a treatment option for pBTs, both in pre-clinical and clinical settings [36,37,38,39]. This evidence concerns the gene MTOR and cancer.